Integra Lifesciences (IART) Tops Q2 EPS by 4c

Integra Lifesciences (NASDAQ: IART) reported Q2 EPS of $0.68, $0.04 better than the analyst estimate of $0.64. Revenue for the quarter came in at $231.4 million versus the consensus estimate of $229.32 million.

For earnings history and earnings-related data on Integra Lifesciences (IART) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Morgan Stanley Downgrades Tryg A/S (TRYG:DC) (TGVSF) to Underweight
• Airbnb Inc. (ABNB) PT Raised to $175 at Jefferies